159 related articles for article (PubMed ID: 18082586)
1. Pelvic lymph node irradiation for prostate cancer: who, why, and when?
Wang D; Lawton C
Semin Radiat Oncol; 2008 Jan; 18(1):35-40. PubMed ID: 18082586
[TBL] [Abstract][Full Text] [Related]
2. [Is pelvic irradiation still justified in the treatment of prostate cancer by exclusive radiotherapy?].
Chapet O; Quero L; Azria D; Bossi A; Hennequin C; Paparel P
Cancer Radiother; 2009 Sep; 13(5):416-22. PubMed ID: 19167919
[TBL] [Abstract][Full Text] [Related]
3. The evolving role of pelvic radiation therapy.
Roberts T; Roach M
Semin Radiat Oncol; 2003 Apr; 13(2):109-20. PubMed ID: 12728440
[TBL] [Abstract][Full Text] [Related]
4. [Locally advanced prostate cancer: definition, prognosis and treatment].
Plantade A; Massard C; de Crevoisier R; Fizazi K
Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
[TBL] [Abstract][Full Text] [Related]
5. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE.
Berglund RK; Sadetsky N; DuChane J; Carroll PR; Klein EA
J Urol; 2007 Feb; 177(2):526-29; discussion 529-30. PubMed ID: 17222625
[TBL] [Abstract][Full Text] [Related]
6. Laparoscopic pelvic lymph-node dissection in prostate cancer before external beam radiotherapy: Risk factors of nodal involvement and relapse following intended curative treatment.
Bjerggaard Jensen J; Johansen JK; Graversen PH
Scand J Urol Nephrol; 2009; 43(1):19-24. PubMed ID: 18752151
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.
Pommier P; Chabaud S; Lagrange JL; Richaud P; Lesaunier F; Le Prise E; Wagner JP; Hay MH; Beckendorf V; Suchaud JP; Pabot du Chatelard PM; Bernier V; Voirin N; Perol D; Carrie C
J Clin Oncol; 2007 Dec; 25(34):5366-73. PubMed ID: 18048817
[TBL] [Abstract][Full Text] [Related]
8. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
10. The role of whole pelvic radiotherapy in locally advanced prostate cancer.
Dirix P; Haustermans K; Junius S; Withers R; Oyen R; Van Poppel H
Radiother Oncol; 2006 Apr; 79(1):1-14. PubMed ID: 16631267
[TBL] [Abstract][Full Text] [Related]
11. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era.
Nguyen PL; Chen MH; Hoffman KE; Katz MS; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):104-9. PubMed ID: 19286330
[TBL] [Abstract][Full Text] [Related]
12. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy.
Shih HA; Harisinghani M; Zietman AL; Wolfgang JA; Saksena M; Weissleder R
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1262-9. PubMed ID: 16253781
[TBL] [Abstract][Full Text] [Related]
13. Impact of common iliac nodal treatment on radiation outcomes in localized prostate cancer.
Soto DE; Glaser S; Roberts RH; Schipper MJ; McLaughlin PW; Ray ME; Sandler HM; Pan CC
Urology; 2008 Feb; 71(2):313-7. PubMed ID: 18308110
[TBL] [Abstract][Full Text] [Related]
14. Lymph node assessment and lymphadenectomy in prostate cancer.
Ordon M; Nam RK
J Surg Oncol; 2009 Mar; 99(4):215-24. PubMed ID: 19170044
[TBL] [Abstract][Full Text] [Related]
15. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions.
Morikawa LK; Roach M
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):6-16. PubMed ID: 21481721
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
17. Radioisotope guided sentinel lymph node dissection in patients with localized prostate cancer: results of the first 100 cases.
Bastide C; Brenot-Rossi I; Garcia S; Rossi D
Eur J Surg Oncol; 2009 Jul; 35(7):751-6. PubMed ID: 18538526
[TBL] [Abstract][Full Text] [Related]
18. The role of pelvic lymphadenectomy for prostate cancer--therapeutic?
Wagner M; Sokoloff M; Daneshmand S
J Urol; 2008 Feb; 179(2):408-13. PubMed ID: 18076938
[TBL] [Abstract][Full Text] [Related]
19. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
Boormans JL; Wildhagen MF; Bangma CH; Verhagen PC; van Leenders GJ
BJU Int; 2008 Dec; 102(11):1589-93. PubMed ID: 18710447
[TBL] [Abstract][Full Text] [Related]
20. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection.
Salonia A; Briganti A; Gallina A; Karakiewicz P; Shariat S; Freschi M; Zanni G; Capitanio U; Bosi E; Rigatti P; Montorsi F
Urology; 2009 Apr; 73(4):850-5. PubMed ID: 19038425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
